1. Состояние онкологической помощи населению России в 2017 году / под ред. Каприна А. Д., Старинского В. В., Петровой Г. В. М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2018. 236 с. [Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2017 godu / рod red. Kaprina A. D., Starinskogo V. V., Petrovoj G. V., M.: MNIOI im. P. A. Gercena — filial FGBU «NMIC radiologii» Minzdrava Rossii. 2018. 236 s. (in Russian)].
2. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2017 // CA Cancer J Clin. 2017. Vol. 67. P.7–30.
3. National Comprehensive Cancer Network. Clinical Practice Guidelines In Oncology: Bladder Cancer, Version 5 [Electronic resource] // URL:
https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed February 19, 2018.
4. Park J. C., Citrin D. E., Agarwal P. K. et al. Multimodal management of muscle-invasive bladder cancer // Curr Probl Cancer. 2014. 38. P.80–108.
5. American Cancer Society. Survival Rates for Bladder Cancer [Electronic resource] //URL:
https://www.cancer.org/cancer/bladder-cancer/detection-diagnosis-staging/survival-rates.html. Accessed February 19, 2018.
6. Sternberg C. N., Yagoda A., Scher H. I. et al. Preliminary results of M–VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium // J Urol. 1985. Vol. 133. P.403–407.
7. Logothetis C. J., Dexeus F. H., Finn L. et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors // J Clin Oncol. 1990. Vol. 8. P.1050–1055.
8. Von der Maase H., Hansen S. W., Roberts J. T. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study // J Clin Oncol. 2000. Vol. 18. P.3068–3077.
9. Sternberg C. N., de Mulder P. H., Schornagel J. H. et al. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924 // J Clin Oncol. 2001. Vol. 19. P.2638–2646.
10. McConkey D.J., Choi W., Shen Y. et al. A prognostic gene expression signature in the molecular classification of chemotherapy-naïve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer // Eur Urol. 2016. Vol. 69. P.855–862.
11. Plimack E. R., Hoffman-Censits J.H., Viterbo R. et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity // J Clin Oncol. 2014. Vol. 32. P.1895–1901.
12. Choueiri T. K., Jacobus S., Bellmunt J. et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates // J Clin Oncol. 2014. Vol. 32. P.1889–1894.
13. Bellmunt J., von der Maase H., Mead G. M. et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987 // J Clin Oncol. 2012. Vol. 30. P.1107–1113.
14. Plimack E. R., Hoffman-Censits J.H., Kutikov A. et al. Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): Final results of a multicenter phase II study // J Clin Oncol. 2014. Vol. 32. 15s. (suppl; abstr 4513). doi:10.1200/jco.2014.32.15_suppl.4513
15. Hussain M., Daignault S., Agarwal N. et al. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer. 2014. Vol. 120. P.2684–2693.
16. Hussain M., Petrylak D., Dunn R. et al. Trastuzumab (T), paclitaxel (P), carboplatin (C) and gemcitabine (G) in advanced HER2-positive urothelial carcinoma: results of a multi-center phase II NCI trial // J Clin Oncol. 2005. Vol. 23 (16_suppl). 379s. doi: 10.1200/jco.2005.23.16_suppl.4507
17. Siefker-Radtke A.O., Millikan R. E., Tu S.– M. et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer // J Clin Oncol. 2002. Vol. 20. P.1361–1367.
18. Galsky M. D., Hahn N. M., Albany C. et al. Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer // J Clin Oncol. 2016. Vol. 34 (2 suppl). P.357–357.
19. Sonpavde G., Galsky M. D., Latini D. et al. Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer // Clin Genitourin Cancer. 2014. Vol. 12. P.71–73.
20. Galsky M. D., Hahn N. M., Rosenberg J. et al. Treatment of patients with metastatic urothelial cancer «unfit» for cisplatin-based chemotherapy // J Clin Oncol. 2011. Vol. 29. P.2432–2438.
21. Bellmunt J., Guillem V., Paz-Ares L. et al. Spanish Oncology Genitourinary Group. Phase I–II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium // J Clin Oncol. 2000. Vol. 18. P.3247–3255.
22. Siefker-Radtke A., Dinney C., Shen Y. et al. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide, in locally advanced urothelial cancer // Cancer. 2013. Vol. 119. P.540–547.
23. Chen M., Kamat A. M., Huang M. et al. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk // Carcinogenesis. 2007. Vol. 28. P.2160–2165.
24. Quintela-Fandino M., Hitt R., Medina P. P. et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy // J Clin Oncol. 2006. Vol. 24. P.4333–4339.
25. Gurubhagavatula S., Liu G., Park S. et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy // J Clin Oncol. 2004. Vol. 22. P.2594–2601.
26. Van Allen E. M., Mouw K. W., Kim P. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma // Cancer Discov. 2014. Vol. 4. P.1140–1153.
27. Groenendijk F. H., de Jong J., Fransen van de Putte E. et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy // Eur Urol. 2016. Vol. 69. P.384–388.
28. Kirkwood J. M., Butterfield L. H., Tarhini A. A. et al. Immunotherapy of cancer in 2012 // CA Cancer J Clin. 2012. Vol. 62. P.309–335.
29. Glaser A. P., Fantini D., Shilatifard A. et al. The evolving genomic landscape of urothelial carcinoma // Nat Rev Urol. 2017. Vol. 14. P.215–229.
30. Lawrence M. S., Stojanov P., Polak P. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes // Nature. 2013. Vol. 499. P.214–218.
31. Гафанов Р. А., Гармаш С. В., Кравцов И. Б., Фастовец С. В. Современные возможности терапии ингибиторами контрольных точек при метастатическом уротелиальном раке // Исследования и практика в медицине. 2018. Т.5 (1). C.74–81. doi: 10.17709/2409–2231–2018–5–1–9. [Gafanov R.A., Garmash S. V., Kravcov I. B., Fastovec S. V. Sovremennye vozmozhnosti terapii ingibitorami kontrol’nyh tochek pri metastaticheskom urotelial’nom rake. Issledovanija i praktika v medicine. 2018. Т.5 (1). S.74–81. doi: 10.17709/2409–2231–2018–5–1–9 (in Russian)].
32. Herbst R. S., Soria J. C., Kowanetz M. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients // Nature. 2014. Vol. 515. P.563–567.
33. Rosenberg J. E., Hoffman-Censits J., Powles T. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial // Lancet. 2016. Vol. 387. P.1909–1920.
34. Ning Y. M., Suzman D., Maher V. E. et al. FDA approval summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy // Oncologist. 2017. Vol. 22. P.743–749.
35. Powles T., Duran I., van der Heijden M. S. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicenter, open-label, phase 3 randomised controlled trial // Lancet. Epub. 2017. Vol. 391 (10122). P.748–757. doi: 10.1016/S0140–6736 (17) 33297-X.
36. Bellmunt J., de Wit R., Vaughn D. J. et al. KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma // N Engl J Med. 2017. Vol. 376. P.1015–1026.
37. Sharma P., Callahan M. K., Bono P. et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial // Lancet Oncol. 2016. Vol. 17. P.1590–1598.
38. Sharma P., Retz M., Siefker-Radtke A. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial // Lancet Oncol. 2017. Vol. 18. P.312–322.
39. Powles T., O’Donnell P.H., Massard C. et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study // JAMA Oncol. 2017. 3. e172411. doi: 10.1001/jamaoncol.2017.2411.
40. Apolo A. B., Infante J. R., Balmanoukian A. et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study // J Clin Oncol. 2017. Vol. 35. P.2117–2124.
41. NCT02603432. A Study of Avelumab in Patients with Locally Advanced or Metastatic Urothelial Cancer (Javelin Bladder 100). A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) Plus Best Supportive Care versus Best Supportive Care Alone as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer Whose Disease Did Not Progress after Completion of First-Line Platinum-Containing Chemotherapy [Electronic resource] // URL:
https://clinicaltrials.gov/ct2/show/NCT02603432. Accessed January 20, 2018.
42. Balar A. V., Galsky M. D., Rosenberg J. E. et al. IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial // Lancet. 2017. Vol. 389. P.67–76.
43. Balar A. V., Castellano D., O’Donnell P.H. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study // Lancet Oncol. 2017. Vol. 18. P.1483–1492.
44. Choi W., Porten S., Kim S. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy // Cancer Cell. 2014. Vol. 25. P.152–165.
45. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma // Nature. 2014. Vol. 507. P.315–322. doi.org/10.1038/nature12965
46. Robertson A. G., Kim J., Al-Ahmadie H. et al. TCGA Research Network. Comprehensive molecular characterization of muscle-invasive bladder cancer // Cell. 2017. Vol. 171. P.540–556. e25.
47. Seiler R., Ashab H. A.D., Erho N. et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy // Eur Urol. 2017. Vol. 72. P.544–554.
48. Diaz L. A., Marabelle A., Delord J-P. et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC // J Clin Oncol. 2017. Vol. 35 P.3071.
49. Shah M. A., Bennouna J., Shen L. et al. Pembrolizumab for previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: phase 2 KEYNOTE-180 study // J Clin Oncol. 2016. Vol. 34 (4_suppl). P.TPS4139.
50. Doi T., Bennouna J., Shen L. et al. KEYNOTE-181: phase 3, open-label study of second-line pembrolizumab vs single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma // J Clin Oncol. 2016. Vol. 34. P.TPS4140.
51. Crew J. P., O’Brien T., Bicknell R. et al. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates // J Urol. 1999. Vol. 161. P.799–804.
52. Nakanishi R., Oka N., Nakatsuji H. et al. Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer // Urol Int. 2009. Vol. 83. P.98–106.
53. Bellmunt J., González-Larriba J.L., Prior C. et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity // Ann Oncol. 2011. Vol. 22. P.2646–2653.
54. Gallagher D. J., Milowsky M. I., Gerst S. R. et al. Phase II study of sunitinib in patients with metastatic urothelial cancer // J Clin Oncol. 2010. Vol. 28. P.1373–1379.
55. Geldart T., Chester J., Casbard A. et al. SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma // Eur Urol. 2015. Vol. 67. P.599–602.
56. Grivas P. D., Daignault S., Tagawa S. T. et al. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma // Cancer. 2014. Vol. 120. P.692–701.
57. Necchi A., Mariani L., Zaffaroni N. et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial // Lancet Oncol. 2012. Vol. 13. P.810–816.
58. Powles T., Huddart R. A., Protheroe A. et al. PLUTO: a randomized phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours // J Clin Oncol 2016. Vol. 34 (suppl; abstr 430).
59. Choueiri T. K., Ross R. W., Jacobus S. et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer // J Clin Oncol. 2012. Vol. 30. P.507–512.
60. Jones R. J., Crabb J. S., Chester J. D. et al. TOUCAN: a randomized phase II trial of carboplatin and gemcitabine +/– vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin // J Clin Oncol 2016. Vol. 34.2s (suppl; abstr 448).
61. Apolo A., Parnes H. A phase II study of cabozantinib in patients with relapsed or refractory metastatic urothelial carcinoma // J Clin Oncol. 2016. Vol. 34 (suppl; abstr 4534).
62. Hahn N. M., Stadler W. M., Zon R. T. et al. Hoosier Oncology Group. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04–75 // J Clin Oncol. 2011. Vol. 29. P.1525–1530.
63. Balar A. V., Apolo A. B., Ostrovnaya I. et al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer // J Clin Oncol. 2013. Vol. 31. P.724–730.
64. Petrylak D. P., Tagawa S. T., Kohli M. et al. Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: an open-label, three-arm, randomized controlled phase II trial // J Clin Oncol. 2016. Vol. 34. P.1500–1509.
65. Petrylak D. P., de Wit R., Chi K. N. et al. RANGE Study Investigators. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial // Lancet. 2017. Vol. 390. P.2266–2277.
66. di Martino E., Tomlinson D. C., Williams S. V. et al. A place for precision medicine in bladder cancer: targeting the FGFRs // Future Oncol. 2016. Vol. 12. P.2243–2263.
67. Van Rhijn B. W.G., Montironi R., Zwarthoff E. C. et al. Frequent FGFR3 mutations in urothelial papilloma // J Pathol. 2002. Vol. 198. P.245–251.
68. van Oers J. M.M., Zwarthoff E. C., Rehman I. et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours // Eur Urol. 2009. Vol. 55. P.650–657.
69. Rebouissou S., Hérault A., Letouzé E. et al. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma // J Pathol. 2012. Vol. 227. P.315–324.
70. Sfakianos J. P., Cha E. K., Iyer G. et al. Genomic characterization of upper tract urothelial carcinoma // Eur Urol. 2015. Vol. 68. P.970–977.
71. Hänze J., Henrici M., Hegele A. et al. Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells // BMC Cancer. 2013. Vol. 13. P.589.
72. Tomlinson D. C., Lamont F. R., Shnyder S. D. et al. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer // Cancer Res. 2009. Vol. 69. P.4613–4620.
73. Tomlinson D. C., Baxter E. W., Loadman P. M. et al. FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms // PLoS One. 2012. 7: e38972. doi.org/10.1371/journal.pone.0038972.
74. Cheng T., Roth B., Choi W. et al. Fibroblast growth factor receptors-1 and –3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting // PLoS One. 2013. Vol. 8: e57284.
75. Milowsky M. I., Dittrich C., Durán I. et al. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma // Eur J Cancer. 2014. Vol. 50. P.3145–3152.
76. Hahn N. M., Bivalacqua T. J., Ross A. E. et al. A phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: Hoosier Cancer Research Network Trial HCRN 12–157 // Clin Cancer Res. 2017. Vol. 23. P.3003–3011.
77. Palma N., Morris J. C., Ali S. M. et al. Exceptional response to pazopanib in a patient with FGFR3 activating mutation and amplification // Eur Urol. 2015. 68. P.168–170.
78. Tabernero J., Bahleda R., Dienstmann R. et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors // J Clin Oncol. 2015. Vol. 33. P.3401–3408.
79. Nogova L., Sequist L. V., Perez Garcia J. M. et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1–3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study // J Clin Oncol. 2017. Vol. 35. P.157–165.
80. Kilgour E., Ferry D., Saggese M. et al. Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors // J Clin Oncol. 2014. Vol. 32 (suppl; abstr 11010). doi:10.11200/jco.2014.32.15_suppl.11010.
81. Voss M. H., Hierro C., Heist R. S. et al. Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase 1 dose-escalation study in patients with FGFR genomically activated advanced solid tumors // J Clin Oncol 2017. P.35 (suppl; abstr 2500).
82. Joerger M., Soo R., Cho B. C. et al. Phase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levels // Ann Oncol 2016. Vol. 27. P.1–36 (abstr 360O).
83. Kuboki Y., Matsubara N., Bando H. et al. First-in-human study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors // Ann Oncol. 2017. P.28 (suppl_5; abstr 372PD).
84. O’Donnell P., Goldman J. W., Gordon M. S. et al. A phase I dose-escalation study of MFGR1877S, a human monoclonal anti-fibroblast growth factor receptor 3 (FGFR3) antibody, in patients with advanced solid tumors // Eur J Cancer. 2012. Vol. 48 (suppl 6). P.191–192.
85. Bellmunt J., Pal S. K., Picus J. et al. Safety and efficacy of docetaxel + B-701, a selective inhibitor of FGFR3, in subjects with advanced or metastatic urothelial carcinoma // J Clin Oncol. 2017. P.35 (suppl; abstr 4540).
86. Morrison K., Challita-Eid P.M., Raitano A. et al. Development of ASG-15ME, a novel antibody-drug conjugate targeting SLITRK6, a new urothelial cancer biomarker // Mol Cancer Ther. 2016. Vol. 15. P.1301–1310.
87. Petrylak D. P., Heath E., Sonpavde G. et al. Interim analysis of a phase 1 dose escalation trial of the antibody drug conjugate AGS-15E (ASG-15ME) in patients with metastatic urothelial carcinoma // Ann Oncol. 2016. Vol. 27 (6). P.266–295 (abstr 780PD).
88. Petrylak D. P., Perez R. P., Zhang J. et al. A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer // J Clin Oncol. 2017. Vol. 35. P.106 (suppl; abstr 106). doi: 10.1200/JCO.2017.35.15_suppl.106.